TABLE 2.
Activity of CD101 and comparator antifungal agents when tested using the CLSI method
| Organism (no. of isolates tested) and antifungal agent | MIC or MEC50 (μg/ml) | MIC or MEC90 (μg/ml) | Range (μg/ml) | % isolates meeting the following CLSI criteriona: |
% isolates meeting the following ECVb: |
|||
|---|---|---|---|---|---|---|---|---|
| S | I/SDD | R | WT | NWT | ||||
| C. albicans (251) | ||||||||
| CD101 | 0.03 | 0.06 | ≤0.008–0.12 | —c | — | — | — | — |
| Anidulafungin | 0.015 | 0.06 | ≤0.008–0.12 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Caspofungind | 0.03 | 0.06 | ≤0.008–0.12 | — | — | — | — | — |
| Micafungin | 0.015 | 0.03 | ≤0.008–0.03 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Fluconazole | ≤0.12 | 0.25 | ≤0.12–>128 | 98.0 | 0.0 | 2.0 | 96.8 | 3.2 |
| Posaconazole | 0.03 | 0.06 | ≤0.008–>8 | — | — | — | 92.4 | 7.6 |
| Voriconazole | ≤0.008 | 0.015 | ≤0.008–>8 | 99.2 | 0.0 | 0.8 | 98.4 | 1.6 |
| Amphotericin B | 1 | 1 | 0.5–1 | — | — | — | 100.0 | 0.0 |
| C. glabrata (100) | ||||||||
| CD101 | 0.03 | 0.06 | 0.015–4 | — | — | — | — | — |
| Anidulafungin | 0.06 | 0.12 | ≤0.008–4 | 95.0 | 0.0 | 5.0 | 95.0 | 5.0 |
| Caspofungind | 0.06 | 0.12 | 0.03–>8 | — | — | — | — | — |
| Micafungin | 0.015 | 0.03 | ≤0.008–4 | 95.0 | 0.0 | 5.0 | 95.0 | 5.0 |
| Fluconazole | 8 | 64 | 0.25–128 | — | 89.0 | 11.0 | 89.0 | 11.0 |
| Posaconazole | 0.5 | 2 | 0.03–4 | — | — | — | 99.0 | 1.0 |
| Voriconazole | 0.12 | 1 | 0.015–4 | — | — | — | 88.0 | 11.0 |
| Amphotericin B | 1 | 1 | 0.5–2 | — | — | — | 100.0 | 0.0 |
| C. parapsilosis (92) | ||||||||
| CD101 | 1 | 2 | 0.5–4 | — | — | — | — | — |
| Anidulafungin | 2 | 4 | 0.5–4 | 82.6 | 17.4 | 0.0 | 100.0 | 0.0 |
| Caspofungind | 0.5 | 1 | 0.25–2 | — | — | — | — | — |
| Micafungin | 1 | 2 | 0.5–2 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Fluconazole | 1 | 2 | 0.25–128 | 95.7 | 0.0 | 4.3 | 95.7 | 4.3 |
| Posaconazole | 0.06 | 0.12 | 0.03–1 | — | — | 98.9 | 1.1 | |
| Voriconazole | 0.015 | 0.03 | ≤0.008–2 | 95.7 | 1.1 | 3.3 | 95.7 | 4.3 |
| Amphotericin B | 1 | 1 | 0.5–1 | — | — | — | 100.0 | 0.0 |
| C. tropicalis (51) | ||||||||
| CD101 | 0.015 | 0.06 | ≤0.008–0.06 | — | — | — | — | — |
| Anidulafungin | 0.015 | 0.03 | ≤0.008–0.06 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Caspofungind | 0.03 | 0.06 | 0.015–0.12 | — | — | — | — | — |
| Micafungin | 0.03 | 0.06 | ≤0.008–0.06 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Fluconazole | 0.5 | 0.5 | ≤0.12–8 | 98.0 | 0.0 | 2.0 | 98.0 | 2.0 |
| Posaconazole | 0.06 | 0.12 | 0.015–0.25 | — | — | — | 98.0 | 2.0 |
| Voriconazole | 0.03 | 0.06 | ≤0.008–0.25 | 98.0 | 0.0 | 2.0 | 94.1 | 5.9 |
| Amphotericin B | 1 | 1 | 0.5–1 | — | — | — | 100.0 | 0.0 |
| C. krusei (16) | ||||||||
| CD101 | 0.03 | 0.06 | 0.015–0.06 | |||||
| Anidulafungin | 0.06 | 0.06 | 0.015–0.06 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Caspofungind | 0.12 | 0.25 | 0.06–0.25 | — | — | — | — | — |
| Micafungin | 0.06 | 0.12 | 0.06–0.12 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Fluconazole | 32 | 32 | 16–64 | — | — | — | 100.0 | 0.0 |
| Posaconazole | 0.25 | 0.5 | 0.03–0.5 | — | — | — | 100.0 | 0.0 |
| Voriconazole | 0.25 | 0.5 | 0.06–0.5 | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 |
| Amphotericin B | 1 | 1 | 1–2 | — | — | — | 100.0 | 0.0 |
| C. dubliniensis (11) | ||||||||
| CD101 | 0.03 | 0.06 | 0.03–0.12 | — | — | — | — | — |
| Anidulafungin | 0.06 | 0.06 | 0.015–0.06 | — | — | — | 100.0 | 0.0 |
| Caspofungind | 0.03 | 0.06 | 0.015–0.06 | — | — | — | — | — |
| Micafungin | 0.03 | 0.03 | 0.015–0.03 | — | — | — | 100.0 | 0.0 |
| Fluconazole | ≤0.12 | ≤0.12 | ≤0.12–0.25 | — | — | — | 100.0 | 0.0 |
| Posaconazole | 0.03 | 0.06 | 0.03–0.06 | — | — | — | 100.0 | 0.0 |
| Voriconazole | ≤0.008 | ≤0.008 | ≤0.008 | — | — | — | 100.0 | 0.0 |
| Amphotericin B | 0.5 | 0.5 | 0.25–1 | — | — | — | 100.0 | 0.0 |
| C. orthopsilosis (10) | ||||||||
| CD101 | 0.5 | 1 | 0.12–2 | — | — | — | — | — |
| Anidulafungin | 0.5 | 1 | 0.25–2 | — | — | — | 100.0 | 0.0 |
| Caspofungind | 0.25 | 0.5 | 0.06–0.5 | — | — | — | — | — |
| Micafungin | 0.5 | 1 | 0.12–1 | — | — | — | 100.0 | 0.0 |
| Fluconazole | 1 | 2 | 0.5–32 | — | — | — | 90.0 | 10.0 |
| Posaconazole | 0.12 | 0.12 | 0.06–0.25 | — | — | — | 100.0 | 0.0 |
| Voriconazole | 0.03 | 0.06 | 0.015–0.5 | — | — | — | 90.0 | 10.0 |
| Amphotericin B | 0.5 | 1 | 0.5–1 | — | — | — | 100.0 | 0.0 |
| C. neoformans var. grubii (19) | ||||||||
| CD101 | >8 | >8 | 8–>8 | — | — | — | — | — |
| Anidulafungin | >8 | >8 | 8–>8 | — | — | — | — | — |
| Caspofungind | >8 | >8 | 8–>8 | — | — | — | — | — |
| Micafungin | >8 | >8 | 8–>8 | — | — | — | — | — |
| Fluconazole | 2 | 4 | 1–4 | — | — | — | 100.0 | 0.0 |
| Posaconazole | 0.12 | 0.25 | 0.03–0.25 | — | — | — | 100.0 | 0.0 |
| Voriconazole | 0.03 | 0.06 | 0.03–0.06 | — | — | — | 100.0 | 0.0 |
| Amphotericin B | 1 | 1 | 0.5–1 | — | — | — | — | — |
| A. fumigatus (56) | ||||||||
| CD101 | 0.015 | 0.015 | ≤0.008–0.03 | — | — | — | — | — |
| Anidulafungin | ≤0.008 | 0.015 | ≤0.008–0.03 | — | — | — | — | — |
| Caspofungind | 0.03 | 0.03 | 0.015–0.06 | — | — | — | — | — |
| Micafungin | 0.015 | 0.015 | ≤0.008–0.03 | — | — | — | — | — |
| Itraconazole | 0.5 | 1 | 0.25–1 | — | — | — | 100.0 | 0.0 |
| Posaconazole | 0.25 | 0.5 | 0.06–0.5 | — | — | — | 100.0 | 0.0 |
| Voriconazole | 0.25 | 0.5 | 0.12–1 | — | — | — | 100.0 | 0.0 |
| Amphotericin B | 2 | 2 | 0.5–2 | — | — | — | 100.0 | 0.0 |
a
Clinical and Laboratory Standards Institute (CLSI) breakpoint criteria. S, susceptible; I/SDD, intermediate/susceptible dose dependent; R, resistant.
b
WT, wild type; NWT, non-wild type.
c
—, not available.
d
Caspofungin interpretative criteria were omitted due to reproducibility issues when this compound was tested (13).